{"id":"methylphenidate-oral-solution","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Insomnia"},{"rate":"15-25","effect":"Decreased appetite"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Nervousness or anxiety"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-15","effect":"Elevated blood pressure"}]},"_chembl":{"chemblId":"CHEMBL796","moleculeType":"Small molecule","molecularWeight":"233.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate is a sympathomimetic amine that inhibits the reuptake transporters for dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced dopaminergic and noradrenergic signaling improves attention, focus, and impulse control. The oral solution formulation allows for flexible dosing and is particularly useful in pediatric populations or patients with difficulty swallowing tablets.","oneSentence":"Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:47.323Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"},{"name":"Narcolepsy"}]},"trialDetails":[{"nctId":"NCT05301361","phase":"PHASE1","title":"Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, Davis","startDate":"2023-02-01","conditions":"Intellectual Disability, Fragile X Syndrome, Down Syndrome","enrollment":68},{"nctId":"NCT04603391","phase":"PHASE4","title":"Cannabidiol and CES1 Interactions in Healthy Subjects","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-02-25","conditions":"Drug Interaction","enrollment":14},{"nctId":"NCT00223691","phase":"PHASE1","title":"Treatment of Orthostatic Hypotension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2002-03","conditions":"Autonomic Failure, Orthostatic Hypotension","enrollment":389},{"nctId":"NCT00904670","phase":"PHASE3","title":"Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-04","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MPH","Ritalin","Concerta","Jornay PM","Biphentin®"],"phase":"marketed","status":"active","brandName":"Methylphenidate Oral Solution","genericName":"Methylphenidate Oral Solution","companyName":"University of California, Davis","companyId":"university-of-california-davis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability at the synapse. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}